Showing 6231-6240 of 7932 results for "".
- Study: Dermatologists Open to AIhttps://practicaldermatology.com/news/study-dermatologists-open-to-ai/2461075/Artificial intelligence (AI) may play a welcome role in dermatology, according to researchers from the George Washington University (GW) School of Medicine and Health Sciences (SMHS). AI, such as machine-learning, which has been incorporated into photography, dermoscopy, and confocal mi
- Juvederm Volbella XC Scores FDA Nod for Undereye Hollowshttps://practicaldermatology.com/news/juvederm-volbella-xc-scores-fda-nod-for-undereye-hollows/2461071/The US Food and Drug Administration has given its nod to Allergan Aesthetics, Juvederm Volbella XC for improvement of infraorbital hollows in adults over the age of 21. Per FDA requirement for this new indication, Allergan Aesthetics is providing a product training
- Leadership Changes Take Place at SkinCeuticalshttps://practicaldermatology.com/news/leadership-changes-at-skinceuticals/2461069/Stephanie Kramer is now SkinCeutical’s Global General Manager, and Amy Sloan is the Head of SkinCeuticals U.S, the company reports Sloan brings 15 years of global and U.S. beauty industry experience - 10 of those years with SkinCeuticals - to the role of Head o
- Study: Nutrafol's Core Products Provide Benefits Across Sexes, Ethnicitieshttps://practicaldermatology.com/news/study-nutrafols-core-products-provide-benefits-across-sexes-ethnicities/2461068/Nutrafol’s core products provide improvement in hair growth, coverage, density, and volume across diverse ethnicities, results of a new study show. The six-month, single blind study was conducted by Dr. Sophia Kogan, Tess Marshall, and Dr. Isabelle Raymond to test the effecti
- Biofrontera Updates Patient Recruitment for Ameluz-PDT Trialhttps://practicaldermatology.com/news/biofrontera-updates-patient-recruitment-for-ameluz-pdt-trial/2461066/Fully 70 percent of the planned 186 patients have been enrolled in Biofrontera Inc.'s phase III clinical study for the treatment of superficial basal cell carcinoma (sBCC) with Ameluz photodynamic therapy (Ameluz-PDT) in combination with the BF-RhodoLED lamp in the U.S, the company repor
- Desert Harvest's Aloe Glide Receives NEA Seal of Acceptancehttps://practicaldermatology.com/news/desert-harvests-aloe-glide-receives-nea-seal-of-acceptance/2461056/Desert Harvest’s Aloe Glide has received the National Eczema Association (NEA) Seal of Acceptance, making it the first sexual lubricant to earn this seal. The NEA Seal appears on products approved by the association to help consumers identify and choose products that are suitable
- New Analysis Ranks Tremfya Highest Among PsA Treatments for Skin Clearancehttps://practicaldermatology.com/news/new-analysis-ranks-tremfya-highest-among-psa-treatments-for-skin-clearance/2461054/Tremfya® (guselkumab) ranks highest for skin clearance, based on Psoriasis (PsO) Area Severity Index (PASI) 90 response, among 23 psoriatic arthritis (PsA) treatment regimens, results of a newly reported Network Meta-Analysis (NMA) show. In terms of joint inflammation
- Nevisense Boosts Clinician Confidence in Early Melanoma Diagnosishttps://practicaldermatology.com/news/nevisense-boosts-clinicians-confidence-in-early-melanoma-diagnosis/2461053/Nevisense provides valuable diagnostic guidance for clinicans when evaluating atypical pigmented skin lesions, according to a new study. The Nevisense method uses small electrical impulses to detect cellular irregularities beneath the skin’s surface. In the pilot study,
- L'Oréal and Verily Partner to Advance Precision Skin Healthhttps://practicaldermatology.com/news/loreal-and-verily-partner-to-advance-precision-skin-health/2461048/L'Oréal and Verily, an Alphabet precision health company are joining forces to advance skin health. The partnership is expected to entail two programs aimed to better understand and characterize skin and hair aging mechanisms and to inform L'Oréal's precis
- UCB Releases Positive Top-line Results for Bimekizumab in Second Phase 3 Psoriatic Arthritis Studyhttps://practicaldermatology.com/news/ucb-releases-positive-top-line-results-for-bimekizumab-in-second-phase-3-psoriatic-arthritis-study/2461047/UCB’s bimekizumab performed well in a Phase 3 study of active psoriatic arthritis patients who were inadequate responders or intolerant to anti-tumor necrosis factor-alpha (anti-TNF-α) therapy. Significantly more patients treated with bimekizumab achieved 50 percent or great